I undersøgelserne af forebyggende anvendelse var Noxafil lige så effektivt som fluconazol hos stam - celletransplanterede patienter, hvor infektion opstod hos 5% af patienterne i Noxafil- gruppen og 9% i sammenligningsgruppen.
In the prevention studies, Noxafil was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Noxafil group, and 9% in the comparator group.